Evommune — Third Quarter 2026 Earnings Summary

Evommune, Inc. reported a net loss of $30.9 million for the third quarter of 2026, with cash and investments totaling $262.3 million as of September 30, 2026. The company in-licensed EVO570, an oral VAV-1 molecular glue degrader, for $30 million and concurrently raised $30 million through a private placement of common stock. Clinical updates include positive Phase 2a data for EVO301 in atopic dermatitis, which supports a Phase 2b trial expected to initiate in mid-2027, alongside plans to begin Phase 1 trials for EVO570 and EVO646 in early 2027.